Latest Pharma Insights
Finance Watch: Searches For Strategic Alternatives End With Many New Reverse Mergers
Restructuring Edition: Companies struggling and running out of cash are increasingly turning to reverse mergers with 10 so far in 2026. Also, Matinas is merging with a clean energy company as it nears the end of its cash runway, while job cuts continue at big pharma firms, including Novartis.
Scrip - July 16, 2026
Restructuring Edition: Companies struggling and running out of cash are increasingly turning to reverse mergers with 10 so far in 2026. Also, Matinas is merging with a clean energy company as it nears the end of its cash runway, while job cuts continue at big pharma firms, including Novartis.
Scrip - July 16, 2026
Execs On The Move: July 6–10, 2026
An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.
Medtech Insight - July 16, 2026
An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.
Medtech Insight - July 16, 2026
Medtronic Closes $650M SPR Therapeutics Deal, Targeting Earlier Entry Point In Chronic Pain
Medtronic has completed its previously announced $650m buyout of SPR Therapeutics, adding SPR’s 60-day non-implantable neuromodulation system to its portfolio. The move comes as consolidation accelerates across the sector with Boston Scientific, Abbott and GE HealthCare making big plays as well.
Medtech Insight - July 16, 2026
Medtronic has completed its previously announced $650m buyout of SPR Therapeutics, adding SPR’s 60-day non-implantable neuromodulation system to its portfolio. The move comes as consolidation accelerates across the sector with Boston Scientific, Abbott and GE HealthCare making big plays as well.
Medtech Insight - July 16, 2026
CMS’s 2027 Fee Schedule Draft Takes Aim At RPM Contractor Model
CMS's draft 2027 physician fee schedule would bar contractors from billing for remote patient monitoring — a direct threat to device companies that built managed-service RPM businesses. OIG fraud findings appear to be driving the change.
Medtech Insight - July 16, 2026
CMS's draft 2027 physician fee schedule would bar contractors from billing for remote patient monitoring — a direct threat to device companies that built managed-service RPM businesses. OIG fraud findings appear to be driving the change.
Medtech Insight - July 16, 2026
BIO 2026: Catching Up With Vaxart, Aphaia, Connect Biopharma, Kyverna And Chugai
Scrip spoke at the BIO International Convention with Vaxart, Aphaia, Connect Biopharma and Kyverna executives about near-term milestones and with Chugai’s Ryuji Hayashi about drug discovery priorities.
Scrip - July 16, 2026
Scrip spoke at the BIO International Convention with Vaxart, Aphaia, Connect Biopharma and Kyverna executives about near-term milestones and with Chugai’s Ryuji Hayashi about drug discovery priorities.
Scrip - July 16, 2026
US Consumer Health Industry News Digest: Business, Regulation, Science
Weekly digest of US consumer health industry, marketplace news for July 13-17: House bills give, take on recycling claims; PE kicks in $1b for Beckham’s IM8; penalty shrunk for supplement firm stretching truth; supply chain latest FDA formula concern; Abbott maintains full-year guidance; more.
HBW Insight - July 16, 2026
Weekly digest of US consumer health industry, marketplace news for July 13-17: House bills give, take on recycling claims; PE kicks in $1b for Beckham’s IM8; penalty shrunk for supplement firm stretching truth; supply chain latest FDA formula concern; Abbott maintains full-year guidance; more.
HBW Insight - July 16, 2026
Lilly To Target Treatment-Resistant Depression With AtaiBeckley Buyout
For up to $3.8bn, Lilly will acquire AtaiBeckley and its Phase III-ready psychedelic drug for TRD as a potential competitor to Johnson & Johnson’s Spravato.
Scrip - July 16, 2026
For up to $3.8bn, Lilly will acquire AtaiBeckley and its Phase III-ready psychedelic drug for TRD as a potential competitor to Johnson & Johnson’s Spravato.
Scrip - July 16, 2026
Kalshi Brings Prediction Markets To Biopharma, But Also Raises Questions
Prediction markets generally have sparked concerns about potential insider trading, though Kalshi has taken steps to limit it.
Scrip - July 16, 2026
Prediction markets generally have sparked concerns about potential insider trading, though Kalshi has taken steps to limit it.
Scrip - July 16, 2026
Component Shortage Slows Remediation Of ResMed Ventilator Safety Issue, FDA Says
A malfunction in certain ResMed ventilators may cause the devices to stop delivering therapy, according to the FDA, which says the issue has been linked to five serious injuries and no reported deaths. Patients should continue using their ventilator unless instructed otherwise by their clinicians.
Medtech Insight - July 16, 2026
A malfunction in certain ResMed ventilators may cause the devices to stop delivering therapy, according to the FDA, which says the issue has been linked to five serious injuries and no reported deaths. Patients should continue using their ventilator unless instructed otherwise by their clinicians.
Medtech Insight - July 16, 2026
Executives On The Move: GSK, Sanofi, Merck Alums Take Top Pharma Roles
Recent moves in the industry include C-suite changes at Illumina, internal C-suite appointments at Ovid Therapeutics, plus Moderna gets a new board member.
Scrip - July 16, 2026
Recent moves in the industry include C-suite changes at Illumina, internal C-suite appointments at Ovid Therapeutics, plus Moderna gets a new board member.
Scrip - July 16, 2026
Academics Propose Higher UK Vit D Threshold To Expose Reality Of Deficiency
A group of UK academics is calling for the vitamin D deficiency threshold to be doubled to 50nmol/L, a change that would classify over half of adults as deficient and strengthen the case for wider supplementation and fortification.
HBW Insight - July 16, 2026
A group of UK academics is calling for the vitamin D deficiency threshold to be doubled to 50nmol/L, a change that would classify over half of adults as deficient and strengthen the case for wider supplementation and fortification.
HBW Insight - July 16, 2026
Abivax Advances R&D Efforts With Valerio RNA pact
Abivax, riding a $920m public offering and regulatory momentum for obefazimod, has teamed up with fellow French RNA biotech Valerio Therapeutics in an immune-mediated inflammation collaboration worth up to €2.4m upfront.
Scrip - July 16, 2026
Abivax, riding a $920m public offering and regulatory momentum for obefazimod, has teamed up with fellow French RNA biotech Valerio Therapeutics in an immune-mediated inflammation collaboration worth up to €2.4m upfront.
Scrip - July 16, 2026
J&J Blames UK Impella Trial For Abiomed Decline As Q2 Cardiovascular Slips
An unfavorable UK clinical trial on J&J's Impella heart device has moved from the medical literature into the company's quarterly results, with slower procedure volumes dragging Abiomed revenue down 2% in Q2 2026 and pushing Cardiovascular growth below its recent trend.
Medtech Insight - July 16, 2026
An unfavorable UK clinical trial on J&J's Impella heart device has moved from the medical literature into the company's quarterly results, with slower procedure volumes dragging Abiomed revenue down 2% in Q2 2026 and pushing Cardiovascular growth below its recent trend.
Medtech Insight - July 16, 2026
Deals In Depth: June 2026
Sixteen $1bn+ alliances were penned in June, and seven exceeded $2bn. In the top alliance by deal value, Haisco Pharmaceutical Group?signed a potential $3.05bn collaboration with?Eli Lilly to develop medicines across multiple therapeutic areas.
In Vivo - July 16, 2026
Sixteen $1bn+ alliances were penned in June, and seven exceeded $2bn. In the top alliance by deal value, Haisco Pharmaceutical Group?signed a potential $3.05bn collaboration with?Eli Lilly to develop medicines across multiple therapeutic areas.
In Vivo - July 16, 2026
Merck & Co.’s Lipfendra Brings First Oral PCSK9 To Market
The company’s oral PCSK9 inhibitor enlicitide was approved by FDA, a key pillar in the company’s cardiovascular pipeline renaissance.
Scrip - July 16, 2026
The company’s oral PCSK9 inhibitor enlicitide was approved by FDA, a key pillar in the company’s cardiovascular pipeline renaissance.
Scrip - July 16, 2026
Hyloris Revives China Ambitions With New Maxigesic Partner
Hyloris’ partner AFT has replaced Maxigesic IV’s previous China licensee with Chengdu Tongde, which will fund development, seek approval and manufacture the product, while Hyloris retains a minority share of future royalties.
Generics Bulletin - July 16, 2026
Hyloris’ partner AFT has replaced Maxigesic IV’s previous China licensee with Chengdu Tongde, which will fund development, seek approval and manufacture the product, while Hyloris retains a minority share of future royalties.
Generics Bulletin - July 16, 2026
Reports: Viatris To Exit Biocon As Biosimilars Competition Reopens Globally
Viatris’ Mylan has sold approximately 92 million Biocon shares in a block deal, fully exiting the Indian manufacturer and completing the monetization of its former Biocon Biologics stake.
Generics Bulletin - July 16, 2026
Viatris’ Mylan has sold approximately 92 million Biocon shares in a block deal, fully exiting the Indian manufacturer and completing the monetization of its former Biocon Biologics stake.
Generics Bulletin - July 16, 2026
Teva Wins Chance To Prove Lilly Delayed Teriparatide Launch
The Seventh Circuit has revived Teva’s claim that Lilly breached a Forteo settlement by delaying generic entry, ruling that the agreement’s duration could not be resolved at the dismissal stage.
Generics Bulletin - July 16, 2026
The Seventh Circuit has revived Teva’s claim that Lilly breached a Forteo settlement by delaying generic entry, ruling that the agreement’s duration could not be resolved at the dismissal stage.
Generics Bulletin - July 16, 2026
Change On The Horizon As Sandoz Shakes Up Management Team
Glenn Gerecke has been replaced as president of generics manufacturing and supply at Sandoz, while North America president Keren Haruvi and transformation and growth head Simon Goeller have been given new responsibilities. What do these changes tell us about Sandoz’s business priorities?
Generics Bulletin - July 16, 2026
Glenn Gerecke has been replaced as president of generics manufacturing and supply at Sandoz, while North America president Keren Haruvi and transformation and growth head Simon Goeller have been given new responsibilities. What do these changes tell us about Sandoz’s business priorities?
Generics Bulletin - July 16, 2026
Paying More, Choosing Less: A Decade Of Deal Data
Evaluate data on nearly 1,200 acquisitions shows pharma writing larger checks for earlier-stage, less-proven assets – and concentrating them in fewer modalities. The 2019 playbook on price, stage and modality no longer holds.
In Vivo - July 16, 2026
Evaluate data on nearly 1,200 acquisitions shows pharma writing larger checks for earlier-stage, less-proven assets – and concentrating them in fewer modalities. The 2019 playbook on price, stage and modality no longer holds.
In Vivo - July 16, 2026
DAC Plots To Come From Behind In Small Cell Lung Cancer ADC Race
As DAC plans a Phase III registrational study in China for its CD56-targeting antibody-drug conjugate DXC006 for second- or later-line ES-SCLC, it sees low toxicity as a potential key advantage for the relative latecomer.
Scrip - July 16, 2026
As DAC plans a Phase III registrational study in China for its CD56-targeting antibody-drug conjugate DXC006 for second- or later-line ES-SCLC, it sees low toxicity as a potential key advantage for the relative latecomer.
Scrip - July 16, 2026
House Democrats Want GAO Study Of US FDA User Fee Spending On Layoffs
Rep. Frank Pallone questioned whether user fees could be spent on severance and other costs related to staff departures.
HBW Insight - July 16, 2026
Rep. Frank Pallone questioned whether user fees could be spent on severance and other costs related to staff departures.
HBW Insight - July 16, 2026
US OTC Monograph Guidance On Formal Meetings Adds IND Studies, Clarifies ‘Joint’ Requests
Final guidance features revisions from 2022 draft including addressing meetings with agency officials to obtain advice on IND applications to support determinations of whether an OTC drug is GRASE, and clarification of eligible participants in “joint meetings.”
HBW Insight - July 16, 2026
Final guidance features revisions from 2022 draft including addressing meetings with agency officials to obtain advice on IND applications to support determinations of whether an OTC drug is GRASE, and clarification of eligible participants in “joint meetings.”
HBW Insight - July 16, 2026
Givaudan, IFF Invest In Scent-Extending Tech; Fragrance Roundup
Givaudan is investing in encapsulation technology that will enhance scent performance, as International Flavors & Fragrances focuses on light-activated fragrance technology and dsm-firmenich rolls out its immersive art-and-fragrance installation.
HBW Insight - July 16, 2026
Givaudan is investing in encapsulation technology that will enhance scent performance, as International Flavors & Fragrances focuses on light-activated fragrance technology and dsm-firmenich rolls out its immersive art-and-fragrance installation.
HBW Insight - July 16, 2026
Finance Watch: Searches For Strategic Alternatives End With Many New Reverse Mergers
Restructuring Edition: Companies struggling and running out of cash are increasingly turning to reverse mergers with 10 so far in 2026. Also, Matinas is merging with a clean energy company as it nears the end of its cash runway, while job cuts continue at big pharma firms, including Novartis.
Scrip - July 16, 2026
Restructuring Edition: Companies struggling and running out of cash are increasingly turning to reverse mergers with 10 so far in 2026. Also, Matinas is merging with a clean energy company as it nears the end of its cash runway, while job cuts continue at big pharma firms, including Novartis.
Scrip - July 16, 2026
BIO 2026: Catching Up With Vaxart, Aphaia, Connect Biopharma, Kyverna And Chugai
Scrip spoke at the BIO International Convention with Vaxart, Aphaia, Connect Biopharma and Kyverna executives about near-term milestones and with Chugai’s Ryuji Hayashi about drug discovery priorities.
Scrip - July 16, 2026
Scrip spoke at the BIO International Convention with Vaxart, Aphaia, Connect Biopharma and Kyverna executives about near-term milestones and with Chugai’s Ryuji Hayashi about drug discovery priorities.
Scrip - July 16, 2026
Lilly To Target Treatment-Resistant Depression With AtaiBeckley Buyout
For up to $3.8bn, Lilly will acquire AtaiBeckley and its Phase III-ready psychedelic drug for TRD as a potential competitor to Johnson & Johnson’s Spravato.
Scrip - July 16, 2026
For up to $3.8bn, Lilly will acquire AtaiBeckley and its Phase III-ready psychedelic drug for TRD as a potential competitor to Johnson & Johnson’s Spravato.
Scrip - July 16, 2026
Kalshi Brings Prediction Markets To Biopharma, But Also Raises Questions
Prediction markets generally have sparked concerns about potential insider trading, though Kalshi has taken steps to limit it.
Scrip - July 16, 2026
Prediction markets generally have sparked concerns about potential insider trading, though Kalshi has taken steps to limit it.
Scrip - July 16, 2026
Executives On The Move: GSK, Sanofi, Merck Alums Take Top Pharma Roles
Recent moves in the industry include C-suite changes at Illumina, internal C-suite appointments at Ovid Therapeutics, plus Moderna gets a new board member.
Scrip - July 16, 2026
Recent moves in the industry include C-suite changes at Illumina, internal C-suite appointments at Ovid Therapeutics, plus Moderna gets a new board member.
Scrip - July 16, 2026
Abivax Advances R&D Efforts With Valerio RNA pact
Abivax, riding a $920m public offering and regulatory momentum for obefazimod, has teamed up with fellow French RNA biotech Valerio Therapeutics in an immune-mediated inflammation collaboration worth up to €2.4m upfront.
Scrip - July 16, 2026
Abivax, riding a $920m public offering and regulatory momentum for obefazimod, has teamed up with fellow French RNA biotech Valerio Therapeutics in an immune-mediated inflammation collaboration worth up to €2.4m upfront.
Scrip - July 16, 2026
Merck & Co.’s Lipfendra Brings First Oral PCSK9 To Market
The company’s oral PCSK9 inhibitor enlicitide was approved by FDA, a key pillar in the company’s cardiovascular pipeline renaissance.
Scrip - July 16, 2026
The company’s oral PCSK9 inhibitor enlicitide was approved by FDA, a key pillar in the company’s cardiovascular pipeline renaissance.
Scrip - July 16, 2026
DAC Plots To Come From Behind In Small Cell Lung Cancer ADC Race
As DAC plans a Phase III registrational study in China for its CD56-targeting antibody-drug conjugate DXC006 for second- or later-line ES-SCLC, it sees low toxicity as a potential key advantage for the relative latecomer.
Scrip - July 16, 2026
As DAC plans a Phase III registrational study in China for its CD56-targeting antibody-drug conjugate DXC006 for second- or later-line ES-SCLC, it sees low toxicity as a potential key advantage for the relative latecomer.
Scrip - July 16, 2026
Execs On The Move: July 6–10, 2026
An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.
Medtech Insight - July 16, 2026
An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.
Medtech Insight - July 16, 2026
Medtronic Closes $650M SPR Therapeutics Deal, Targeting Earlier Entry Point In Chronic Pain
Medtronic has completed its previously announced $650m buyout of SPR Therapeutics, adding SPR’s 60-day non-implantable neuromodulation system to its portfolio. The move comes as consolidation accelerates across the sector with Boston Scientific, Abbott and GE HealthCare making big plays as well.
Medtech Insight - July 16, 2026
Medtronic has completed its previously announced $650m buyout of SPR Therapeutics, adding SPR’s 60-day non-implantable neuromodulation system to its portfolio. The move comes as consolidation accelerates across the sector with Boston Scientific, Abbott and GE HealthCare making big plays as well.
Medtech Insight - July 16, 2026
CMS’s 2027 Fee Schedule Draft Takes Aim At RPM Contractor Model
CMS's draft 2027 physician fee schedule would bar contractors from billing for remote patient monitoring — a direct threat to device companies that built managed-service RPM businesses. OIG fraud findings appear to be driving the change.
Medtech Insight - July 16, 2026
CMS's draft 2027 physician fee schedule would bar contractors from billing for remote patient monitoring — a direct threat to device companies that built managed-service RPM businesses. OIG fraud findings appear to be driving the change.
Medtech Insight - July 16, 2026
Component Shortage Slows Remediation Of ResMed Ventilator Safety Issue, FDA Says
A malfunction in certain ResMed ventilators may cause the devices to stop delivering therapy, according to the FDA, which says the issue has been linked to five serious injuries and no reported deaths. Patients should continue using their ventilator unless instructed otherwise by their clinicians.
Medtech Insight - July 16, 2026
A malfunction in certain ResMed ventilators may cause the devices to stop delivering therapy, according to the FDA, which says the issue has been linked to five serious injuries and no reported deaths. Patients should continue using their ventilator unless instructed otherwise by their clinicians.
Medtech Insight - July 16, 2026
J&J Blames UK Impella Trial For Abiomed Decline As Q2 Cardiovascular Slips
An unfavorable UK clinical trial on J&J's Impella heart device has moved from the medical literature into the company's quarterly results, with slower procedure volumes dragging Abiomed revenue down 2% in Q2 2026 and pushing Cardiovascular growth below its recent trend.
Medtech Insight - July 16, 2026
An unfavorable UK clinical trial on J&J's Impella heart device has moved from the medical literature into the company's quarterly results, with slower procedure volumes dragging Abiomed revenue down 2% in Q2 2026 and pushing Cardiovascular growth below its recent trend.
Medtech Insight - July 16, 2026
US Consumer Health Industry News Digest: Business, Regulation, Science
Weekly digest of US consumer health industry, marketplace news for July 13-17: House bills give, take on recycling claims; PE kicks in $1b for Beckham’s IM8; penalty shrunk for supplement firm stretching truth; supply chain latest FDA formula concern; Abbott maintains full-year guidance; more.
HBW Insight - July 16, 2026
Weekly digest of US consumer health industry, marketplace news for July 13-17: House bills give, take on recycling claims; PE kicks in $1b for Beckham’s IM8; penalty shrunk for supplement firm stretching truth; supply chain latest FDA formula concern; Abbott maintains full-year guidance; more.
HBW Insight - July 16, 2026
Academics Propose Higher UK Vit D Threshold To Expose Reality Of Deficiency
A group of UK academics is calling for the vitamin D deficiency threshold to be doubled to 50nmol/L, a change that would classify over half of adults as deficient and strengthen the case for wider supplementation and fortification.
HBW Insight - July 16, 2026
A group of UK academics is calling for the vitamin D deficiency threshold to be doubled to 50nmol/L, a change that would classify over half of adults as deficient and strengthen the case for wider supplementation and fortification.
HBW Insight - July 16, 2026
House Democrats Want GAO Study Of US FDA User Fee Spending On Layoffs
Rep. Frank Pallone questioned whether user fees could be spent on severance and other costs related to staff departures.
HBW Insight - July 16, 2026
Rep. Frank Pallone questioned whether user fees could be spent on severance and other costs related to staff departures.
HBW Insight - July 16, 2026
US OTC Monograph Guidance On Formal Meetings Adds IND Studies, Clarifies ‘Joint’ Requests
Final guidance features revisions from 2022 draft including addressing meetings with agency officials to obtain advice on IND applications to support determinations of whether an OTC drug is GRASE, and clarification of eligible participants in “joint meetings.”
HBW Insight - July 16, 2026
Final guidance features revisions from 2022 draft including addressing meetings with agency officials to obtain advice on IND applications to support determinations of whether an OTC drug is GRASE, and clarification of eligible participants in “joint meetings.”
HBW Insight - July 16, 2026
Givaudan, IFF Invest In Scent-Extending Tech; Fragrance Roundup
Givaudan is investing in encapsulation technology that will enhance scent performance, as International Flavors & Fragrances focuses on light-activated fragrance technology and dsm-firmenich rolls out its immersive art-and-fragrance installation.
HBW Insight - July 16, 2026
Givaudan is investing in encapsulation technology that will enhance scent performance, as International Flavors & Fragrances focuses on light-activated fragrance technology and dsm-firmenich rolls out its immersive art-and-fragrance installation.
HBW Insight - July 16, 2026
Hyloris Revives China Ambitions With New Maxigesic Partner
Hyloris’ partner AFT has replaced Maxigesic IV’s previous China licensee with Chengdu Tongde, which will fund development, seek approval and manufacture the product, while Hyloris retains a minority share of future royalties.
Generics Bulletin - July 16, 2026
Hyloris’ partner AFT has replaced Maxigesic IV’s previous China licensee with Chengdu Tongde, which will fund development, seek approval and manufacture the product, while Hyloris retains a minority share of future royalties.
Generics Bulletin - July 16, 2026
Reports: Viatris To Exit Biocon As Biosimilars Competition Reopens Globally
Viatris’ Mylan has sold approximately 92 million Biocon shares in a block deal, fully exiting the Indian manufacturer and completing the monetization of its former Biocon Biologics stake.
Generics Bulletin - July 16, 2026
Viatris’ Mylan has sold approximately 92 million Biocon shares in a block deal, fully exiting the Indian manufacturer and completing the monetization of its former Biocon Biologics stake.
Generics Bulletin - July 16, 2026
Teva Wins Chance To Prove Lilly Delayed Teriparatide Launch
The Seventh Circuit has revived Teva’s claim that Lilly breached a Forteo settlement by delaying generic entry, ruling that the agreement’s duration could not be resolved at the dismissal stage.
Generics Bulletin - July 16, 2026
The Seventh Circuit has revived Teva’s claim that Lilly breached a Forteo settlement by delaying generic entry, ruling that the agreement’s duration could not be resolved at the dismissal stage.
Generics Bulletin - July 16, 2026
Change On The Horizon As Sandoz Shakes Up Management Team
Glenn Gerecke has been replaced as president of generics manufacturing and supply at Sandoz, while North America president Keren Haruvi and transformation and growth head Simon Goeller have been given new responsibilities. What do these changes tell us about Sandoz’s business priorities?
Generics Bulletin - July 16, 2026
Glenn Gerecke has been replaced as president of generics manufacturing and supply at Sandoz, while North America president Keren Haruvi and transformation and growth head Simon Goeller have been given new responsibilities. What do these changes tell us about Sandoz’s business priorities?
Generics Bulletin - July 16, 2026
Deals In Depth: June 2026
Sixteen $1bn+ alliances were penned in June, and seven exceeded $2bn. In the top alliance by deal value, Haisco Pharmaceutical Group?signed a potential $3.05bn collaboration with?Eli Lilly to develop medicines across multiple therapeutic areas.
In Vivo - July 16, 2026
Sixteen $1bn+ alliances were penned in June, and seven exceeded $2bn. In the top alliance by deal value, Haisco Pharmaceutical Group?signed a potential $3.05bn collaboration with?Eli Lilly to develop medicines across multiple therapeutic areas.
In Vivo - July 16, 2026
Paying More, Choosing Less: A Decade Of Deal Data
Evaluate data on nearly 1,200 acquisitions shows pharma writing larger checks for earlier-stage, less-proven assets – and concentrating them in fewer modalities. The 2019 playbook on price, stage and modality no longer holds.
In Vivo - July 16, 2026
Evaluate data on nearly 1,200 acquisitions shows pharma writing larger checks for earlier-stage, less-proven assets – and concentrating them in fewer modalities. The 2019 playbook on price, stage and modality no longer holds.
In Vivo - July 16, 2026